Weil Company’s Ionis Pharmaceuticals IONS Stock Holding History

Weil Company’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-120	Closed	-$7K	–	214
2019 Q3	$7K	Buy	+120	New	+$7.82K	0.01%	314

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Weil Company's IONS Position: Q4 2019 in Review

Weil Company sold out of Ionis Pharmaceuticals (IONS) in Q4 2019, closing a stake of 120 shares — an estimated $7K sold.

Weil Company first reported a position in IONS in Q3 2019 and held it in 1 quarter. The position peaked at $7K in Q3 2019. 390 funds tracked by Wall St. Rank hold IONS as of Q4 2019.

Weil Company reported no remaining Ionis Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Weil Company sold 120 Ionis Pharmaceuticals shares in Q4 2019, an estimated $7K.
Weil Company first reported a position in Ionis Pharmaceuticals in Q3 2019 and held it in 1 quarter.
Weil Company's Ionis Pharmaceuticals position peaked at $7K in Q3 2019.
390 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2019.

Based on Weil Company's 13F filing for Q4 2019, filed 13 Feb 2020.